Uncategorized

New Criteria for COVID-19 Therapeutics

Remdesivir – Duration limited to 5 days

Patients must have all of these:

1. Early disease, 10 days or less from beginning of symptoms or positive test (whichever comes first), not hospitalization

2. Hypoxemia, which is a drop of O2 sat to 93% or lower on RA, or a sustained increase in baseline oxygen needs, if on chronic oxygen

Patients must not have any of these:

1. Previous remdesivir therapy within the past 12 months

2. Severe disease, as evidenced by ARDS, MOSF, ECMO, or intubated more than 7 days

3. AST/ALT > 10 times upper limit of normal (about 500)

4. eGFR < 30 or dialysis

Convalescent Plasma – Maximum 2 units, no repeat dosing

Patients must have all of these:

1. Early disease, 5 days or less from beginning of symptoms or positive test (whichever is first), not hospitalization

2. Hypoxemia, which is a drop of O2 sat to 93% or lower on RA, or a sustained increase in baseline oxygen needs, if on chronic oxygen

3. Must have a positive SARS-CoV-2 test

Use of these modalities will continue to be audited. Please do not deviate from these guidelines without literature-based indications.

December 9, 2020